Alnylam Pharmaceuticals, Inc.
ALNY · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $1,249,026 | $773,689 | $594,189 | $593,166 |
| % Growth | 61.4% | 30.2% | 0.2% | – |
| Cost of Goods Sold | $197,231 | $142,953 | $71,041 | $102,817 |
| Gross Profit | $1,051,795 | $630,736 | $523,148 | $490,349 |
| % Margin | 84.2% | 81.5% | 88% | 82.7% |
| R&D Expenses | $358,814 | $323,621 | $265,122 | $300,169 |
| G&A Expenses | $322,076 | $323,314 | $239,949 | $295,339 |
| SG&A Expenses | $322,076 | $323,314 | $239,949 | $295,339 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $2,923 | $0 | $0 | $0 |
| Operating Expenses | $683,813 | $646,935 | $505,071 | $595,508 |
| Operating Income | $367,982 | -$16,199 | $18,077 | -$105,159 |
| % Margin | 29.5% | -2.1% | 3% | -17.7% |
| Other Income/Exp. Net | -$129,013 | -$19,159 | -$59,673 | -$88,799 |
| Pre-Tax Income | $238,969 | -$35,358 | -$41,596 | -$193,958 |
| Tax Expense | -$12,115 | $30,919 | $15,883 | -$110,195 |
| Net Income | $251,084 | -$66,277 | -$57,479 | -$83,763 |
| % Margin | 20.1% | -8.6% | -9.7% | -14.1% |
| EPS | 1.91 | -0.51 | -0.44 | -0.65 |
| % Growth | 474.5% | -15.9% | 32.3% | – |
| EPS Diluted | 1.84 | -0.51 | -0.44 | -0.65 |
| Weighted Avg Shares Out | 131,447 | 129,676 | 129,676 | 128,590 |
| Weighted Avg Shares Out Dil | 137,348 | 129,676 | 129,676 | 128,590 |
| Supplemental Information | – | – | – | – |
| Interest Income | $28,681 | $27,486 | $28,673 | $31,019 |
| Interest Expense | $44,398 | $40,246 | $38,646 | $38,971 |
| Depreciation & Amortization | $13,803 | $13,944 | $14,405 | $14,168 |
| EBITDA | $297,170 | $18,832 | $11,455 | -$140,911 |
| % Margin | 23.8% | 2.4% | 1.9% | -23.8% |